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 Abstract 
  Background:   It has been suggested that low cholesterol levels might be associated with an in-
creased risk of hemorrhagic transformation (HT) in patients with acute cerebral ischemia. We 
systematically reviewed the literature to determine the influence of lipid profiles on the HT risk. 
  Methods:  We searched PubMed from 1966 and EMBASE from 1980 for studies that investigated 
the association between lipid profiles and HT. We performed a meta-analysis (weighted mean 
difference method) for the comparison between presence and absence of HT (all or symptom-
atic) for total, low-density-lipoprotein (LDL) and high-density-lipoprotein (HDL) cholesterol, 
and triglycerides.  Results:  Eight studies investigating 1,763 patients were eligible, but none was 
designed specifically to address this question. All studies recruited acute stroke patients select-
ed on the presumed cause of cerebral ischemia or treatment received. The meta-analysis 
showed that: (i) patients with all HT had lower LDL cholesterol levels (p = 0.008) but no differ-
ence in HDL cholesterol levels (p = 0.066), total cholesterol (p = 0.129) and triglycerides (p = 
0.900); (ii) patients with symptomatic HT had lower total cholesterol levels (p = 0.035) but did 
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not differ in LDL (p = 0.056) and HDL cholesterol (p = 0.138) and triglyceride (p = 0.851) levels. 
  Conclusion:  HT is associated with baseline total and LDL cholesterol levels, but the mechanism 
of this association needs to be explored to identify preventive strategies. 
  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
  Hemorrhagic transformation (HT) of cerebral ischemia may occur either spontaneous-
ly or after treatment with recombinant tissue plasminogen activator (rt-PA)   [1–3]  . Although 
HT may sometimes be related to early recanalization and associated with better clinical out-
comes  [4] , it is more often a predictor of worst clinical outcomes  [2] . HT is favored by increas-
ing age   [2]  , stroke severity   [5]  , blood pressure   [6]   and blood glucose level   [7]  . Identifying 
other factors predisposing to HT may lead to new preventive strategies. The risk of sponta-
neous intracerebral hemorrhage (ICH) increases with lower total cholesterol levels in hu-
mans   [8]   and animals   [9]  , but not in patients treated with intensive lipid-lowering therapy 
after ischemic stroke   [10]  .
  We systematically reviewed published studies to determine the influence of lipid profiles 
on the risk of HT.
  M e t h o d s  
 Literature  Search  Strategy   
      On March 2, 2011, we searched MEDLINE (http://www.ncbi.nlm.nih.gov/pubmed) 
from 1966 and EMBASE (http://ovidsp.ovid.com) from 1980 for studies that investigated the 
association between lipid profiles and HT in patients with acute cerebral ischemia. Because 
there is no medical subject heading (Mesh) term for HT, the search strategy in MEDLINE 
was based on the association of the following terms: [‘Stroke’ (Mesh) OR ‘Cerebral Infarction’ 
(Mesh) OR ‘Infarction, Middle Cerebral Artery’ (Mesh) OR ‘Brain Ischemia’ (Mesh) OR ‘In-
tracranial Hemorrhages’ (Mesh)] AND [‘Lipids’ (Mesh) OR ‘Cholesterol’ (Mesh) OR ‘Cho-
lesterol, HDL’ (Mesh) OR ‘Cholesterol, LDL’ (Mesh) OR ‘Triglycerides’ (Mesh)]. In EMBASE, 
the search strategy was: stroke (exp) AND (lipid or cholesterol or HDL or high density lipo-
protein or LDL or low density lipoprotein or triglycerides).
Studies missed by the electronic search have been identified from the authors’ personal 
files and by hand searching the references cited in retrieved articles. We excluded abstracts 
of meetings and book chapters. We did not exclude any language. One reviewer (K.N.) per-
formed the literature search and screened the titles and abstracts of retrieved citations to 
identify potentially suitable studies. The abstracts were read by 2 reviewers (K.N. and D.L.). 
Uncertainties and disagreements were resolved by consensus. The 2 reviewers extracted data 
from included studies.   
    Inclusion and Exclusion Criteria 
  Studies meeting the following criteria were included in the analysis: (i) adult patients 
with acute cerebral ischemia; (ii) a systematic search for HT in ischemic stroke patients; 
(iii) data on total cholesterol, and/or LDL and/or HDL cholesterol, and/or triglycerides, and 
(iv) a computed tomography (CT) or magnetic resonance imaging (MRI) scan of the brain 
for the assessment of HT. We excluded studies (i) published as reviews; (ii) including pa-
tients with intracranial hemorrhages of other origin than HT, and (iii) based only on au-
topsies.132
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  Critical  Appraisal 
  The external validity of the studies was defined as follows: level A for population-based 
studies recruiting consecutive patients; level B for hospital-based studies recruiting consecu-
tive patients; level C for hospital-based studies recruiting a subgroup of consecutive patients 
encountered with a high frequency (e.g. treated by intravenous rt-PA and age  1 45 years), and 
level D for either nonconsecutive patients or patients from a rare subgroup (e.g. patients 
treated by intra-arterial recanalization).
   Statistical  Analysis 
  The first step consisted of reporting for each eligible study, the mean values (SD) of total, 
LDL and HDL cholesterol, and triglyceride levels separately for patients with and without all 
types of HT (  all  HT), then separately for those with symptomatic HT (  s HT).
    The second step consisted of a meta-analysis of eligible studies for the comparison be-
tween   all  HT versus no HT, for total, LDL and HDL cholesterol, and triglyceride levels, then 
between   s  HT and absence of   s  HT for the same variables. We used the weighted mean differ-
ence (WMD) method. The research question for the meta-analysis was the influence of base-
line levels of lipids on the risk of HT. The comparison was performed between HT and non-
HT patients (then between   s  HT and asymptomatic HT patients). The outcome was the base-
line level of lipids (total, LDL and HDL cholesterol, and triglycerides evaluated separately). 
Statistical significance of the overall results was expressed with the p     value in the test for 
overall effect, with p  !  0.05 being considered as statistically significant. According to ranges 
for interpretation    of  I 2   following the   Cochrane Handbook for Systematic Reviews of Interven-
tions   [11]  ,  I  2  values  ^ 40% were considered as indicating homogeneity between studies. When 
I  2  was  ^ 40% (p values are reported and p  1  0.05 show evidence of no heterogeneity), we used 
a fixed model for meta-analysis. Statistics were performed with the STATA 11 software. The 
analysis was conducted according to the MOOSE consensus   [12]  .
  R e s u l t s  
  The flow chart of the selection of studies is reported in   figure 1  . Eight studies gathering 
1,763 patients were eligible   [13–20]  .
  Critical  Appraisal 
 Most patients included in these studies were recruited between 2000 and 2007  [13–20] . All 
studies were published between 2007 and 2009  [13–20] . Of the 8 studies selected  [13–20] , 3 were 
from the same research group   [13, 18, 19]  . Two of them (including 168 patients) were not in-
cluded in the meta-analysis because they did not provide comparisons between patients with 
and without HT. There might be a possible overlap between these 3 studies including 104, 142 
and 26 patients, precluding all influence on the meta-analysis   [13, 18, 19]  . Only 1 study had a 
multicenter design   [20]  , and none was international. None of these 8 studies was conducted in 
the setting of a clinical trial. Patients were consecutively recruited in 5 studies   [13, 15–17, 20]  , 
not in 2   [18, 19]  , and the information was not reported in 1   [14]  . Patients were, however, pro-
spectively recruited in all studies   [13–20]  . The lipid profile was not determined specifically to 
address the question of the relationship with HT in 7 of the 8 studies   [14–20]  . Whether it was 
a prespecified question remains uncertain in 1 study   [13]  . Five were sponsored by public or in-
stitutional grants   [13, 15, 16, 18, 19]  , and no detail on sponsoring was provided in 3   [14, 17, 20]  .
    The characteristics of patients are detailed in   table 1 .
  In 4 studies, patients were in the fasting state  [13, 18–20] . Previous hypercholesterolemia 
was reported in 6 studies   [14–16, 18–20]  , and ongoing statin therapy in all but 1 study   [17]  . 133
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No information about ongoing fibrate therapy or diet before stroke onset was available in any 
study. The method used to analyze lipids was detailed in 1 study   [15]  . All studies reported 
detailed results for LDL cholesterol levels   [13–20]  , 7 for total cholesterol   [13–19]  , 6 for HDL 
cholesterol   [13–17, 19]   and 5 for triglycerides   [13–17]  .
  The methods used to assess HT are detailed in  table 2 , and associated risk factors for HT 
are detailed in   table 3  . The methods used for analysis in each individual study are detailed 
in   table 4 .
    Statistical Analysis of the Results of Included Studies 
  Individual Studies.   The comparison of lipid profiles was possible in 2 studies   [16, 17]   for 
  all  HT versus no HT, and in 4 for   s  HT versus no   s HT   [13–15,  17]   ( table 5 ).
   Meta-Analysis.   The meta-analysis of comparisons of lipid profiles in patients with and 
without   all  HT included 2 studies   [16, 17]   gathering 688 patients. Detailed results are present-
ed in   figure 2   and   table 5  . LDL cholesterol levels were significantly lower in patients with 
  all  HT (p = 0.008), but not total cholesterol (p = 0.129), HDL cholesterol (p = 0.066) and tri-
glycerides (p = 0.900).
    The meta-analysis of lipid levels in patients with and without   s  HT included 4 studies 
  [13–15, 17]  . These 4 studies included 727 patients   [13–15, 17]  . One study   [14]   provided only 
mean values and no standard deviation. We used for this meta-analysis the standard devia-
tion found in the study with the closest number of patients   [13]  . The detailed results are pre-
  Fig. 1.   Flow chart of the selection of articles. 134
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sented in  figure 3  and  table 5 . Total cholesterol levels were significantly lower in patients with 
  s  HT (p = 0.035), while LDL (p = 0.056) and HDL cholesterol (p = 0.138), and triglyceride lev-
els did not differ (p = 0.851).
  Discussion 
 This meta-analysis suggested that lower LDL cholesterol levels are associated with   all HT, 
while lower total cholesterol levels are associated with   s HT, and HDL cholesterol and triglyc-
erides are not associated with the HT risk.
    Methodology of Selected Studies 
  None of the 8 studies meeting the selection criteria   [13–15, 17]   was primarily designed 
to evaluate lipid profiles in HT explaining missing data, and there was heterogeneity for the 
assessment of HT. Most predictors of HT were taken into account except for silent vascular 
brain lesions, but a multivariate analysis including these predictors was available in only half 
of the studies. The external validity of the study population is therefore poor.
    The method used to analyze serum lipids was usually not detailed, and the delay be-
tween stroke onset and sample collection ranged from admission to the next morning or 7 
days.    A previous study suggested changes in cholesterol levels at the acute stage of stroke  [21] , 
Table 1. S  tudy population
Bang
et al. [13]
Montaner
[14]
Uyttenboogaart
et al. [15]
Kim
et al. [16]
Meier
et al. [17]
Restrepo
et al. [18]
Bang
et al. [19]
Paciaroni
et al. [20]
2007 2008 2008 2009 2009 2009 2009 2009
(n = 104) (n = 60)a (n = 252)b (n = 377) (n = 311) (n = 142) (n = 26)c (n = 491)d
Participants AIS treated
by IVT or
IAT and/or
angioplasty
AIS treated
by IVT
AIS treated
by IVT
Ath. and
CE AIS
AIS treated
by IAT or
angioplasty
AIS treated
by IAT or
angioplasty
AIS with
abnormal BBB
permeability
on 1st MRI
Ath. and
CE AIS
External validity C C C C D D D C
Time from onset to 
admission 
<3 h (IVT),
<8 h
(angioplasty)
<3 h <4.5 h ≤7 days <6 h (anterior
stroke), <12 h
(posterior stroke)
<12 h <24 h <12 h
Time of blood
sampling reported
next
morning
admission admission admission admission next
morning
? next
morning
TIA excluded + + + + + + + +
Recurrent stroke excluded – – –– – – ––
Mean age, years 70.5 ? 68 66 63 69 ? ?
Male gender, % 49 ? 54 62 57 51 ? ?
Healthy controls – – –– – – ––
Controls without HT + + + + + + + +
+   = Characteristic fulfilled; – = characteristic not fulfilled; ? = unknown; AIS = acute ischemic stroke; Ath. = atherosclerotic; CE = cardio-
embolic; IVT = intravenous thrombolytic therapy; IAT = intra-arterial thrombolytic therapy; TIA = transient ischemic attack; BBB = blood-brain 
barrier. External validity was determined as follows: level A for population-based studies recruiting consecutive ischemic stroke patients; level 
B for hospital-based studies recruiting consecutive ischemic stroke patients; level C for hospital-based studies recruiting a subgroup of consecu-
tive ischemic stroke patients considered by the investigator as encountered with a high frequency in practice (e.g. patients treated with IV t-PA 
or patients >45 years), and level D for either nonconsecutive patients or patients from a subgroup considered by the investigator as infrequent in 
practice (e.g. patients treated by intra-arterial recanalization or patients <45 years).
a Among 145 patients, 60 were evaluated for the association between HT and lipid profile.
b Among 301 patients, 252 were evaluated for the association between HT and lipid profile.
c Among 127 patients, 26 were evaluated for the association between HT and lipid profile. 
d Among 1,125 patients, 491 were evaluated for the association between HT and lipid profile. 135
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but as this change is minimal   [22]  , this has probably not had any influence on the results. 
Information on ongoing statin and fibrate therapy, and diet was not available in any study. 
This may have influenced the results, as statins and potentially fibrates may be associated 
with a better outcome in ischemic stroke   [23, 24]  .
    Relationship between Lipid Profiles and HT 
  It was not possible to analyze separately patients with and without reperfusion therapy, 
and according to the type of reperfusion therapy, because individual data were not available, 
and this would have led to subgroup analyses with a poor statistical power.
    The meta-analysis showed a significant association between a low LDL cholesterol level 
and the presence of   all  HT, and between a low total cholesterol level and the presence of   s HT. 
These results are important, because 1 of the 2 individual studies included in the meta-anal-
ysis for   all  HT showed a nonsignificant tendency   [17]   and the other   [16]   was marginally sig-
Table 2. H  T assessment 
Bang
et al. [13]
Montaner
[14]
Uyttenboogaart
et al. [15]
Kim
et al. [16]
Meier
et al. [17]
Restrepo
et al. [18]
Bang
et al. [19]
Paciaroni
et al. [20]
2007 2008 2008 2009 2009 2009 2009 2009
(n = 104) (n = 60)a (n = 252)b (n = 377) (n = 311) (n = 142) (n = 26)c (n = 491)d
Admission imaging showing 
no bleeding
++ + + + + + +
Assessed by CT + ? + – + + + +
Assessed by MRI + ? – + + + + –
Delay between stroke onset and
assessment of HT
24–120 h
or worsening
? in case of
worsening
<168 h 24 h or
worsening
immediately
after treatment
24 h or
worsening
72–168 h
Inter- and intra-observer
agreement evaluated
–– – – – – – +
Follow-up >95% complete until
the date of assessment of HT
++ ? + + + + +
Clear definition for HT + – +2  +3 +4 +5 +6 +7
Clear definition for sHT +1 –+ 2 –+ 4 +5 –+ 7
HT proven to occur in the same
area as the ischemic event
–– – – – – + +
+    = Characteristics fulfilled; – = characteristics not fulfilled; ? =  unknown. 
a Among 145 patients, 60 were evaluated for the association between HT and lipid profile. 
b Among 301 patients, 252 were evaluated for the association between HT and lipid profile. 
c Among 127 patients, 26 were evaluated for the association between HT and lipid profile. 
d Among 1,125 patients, 491 were evaluated for the association between HT and lipid profile. 
1 Radiologically subcategorized as petechial HT or hematoma. Clinical categories for HT defined as asymptomatic HT (i.e. no clinical wors-
ening on NIHSS); minor symptomatic HT (1- to 3-point increase in NIHSS score); major symptomatic HT (4-point increase in NIHSS score or 
1-point deterioration in level of consciousness, and any symptomatic HT (any clinical worsening associated with HT, either major or minor).
2 sHT defined as a neurological deterioration within 48 h following rt-PA therapy with hematoma on CT scan. 
3 HT defined as absent or present on MRI. 
4 HT classified as symptomatic if parenchymal hematoma (PH) type 2 (PH-2) according to ECASS-II accompanied by an increase ≥4 points 
in NIHSS score or leading to death (SIST-MOST). 
5 sHT defined as any acute intraparenchymal bleeding associated with worsening ≥4 points compared to the baseline NIHSS score. 
6 HT was radiologically defined and classified into 5 subtypes modified from Berger et al. [28]: hemorrhagic infarct (HI) type 1 (HI-1); small 
petechiae along the margins of the infarct; HI type 2 (HI-2); more confluent petechiae within the infarcted area but without space-occupying 
effect; PH type 1 (PH-1), defined as a hematoma in <30% of the infarcted area with some space-occupying effect; PH-2, hematoma in >30% or 
the infarcted area with substantial space-occupying effect, and subarachnoid hemorrhage. Patients could have >1 hemorrhage type. 
7 HT defined as any degree of hyperdensity within the area of low attenuation, and categorized as HI or PH. HI was defined as small pete-
chiae along the margins of the infarct (HI-1) or as more confluent petechiae within the infarcted area but without space-occupying effect (HI-2). 
PH was defined as hematoma in 30% of the infarcted area with some slight space-occupying effect (PH-1) or as dense hematoma of ≥30% of the 
infarcted area with substantial space-occupying effect or as any hemorrhagic lesion outside the infarcted area (PH-2). In case of >1 hemorrhagic 
lesion on CT examination, the worst possible HT category was assumed. For analysis purposes, the authors considered HI-1 and HI-2 together 
and PH-1 and PH-2 together. HT was considered symptomatic if it was not seen on a previous CT and there was subsequently either a suspicion 
of hemorrhage or a decline in the neurological status.136
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nificant. The influence of HDL cholesterol seems more disputable because none of the stud-
ies has shown any significant result for both   all  HT and   s  HT, and the meta-analyses provided 
nonsignificant results in opposite directions. There is no statistical association between base-
line triglycerides and risk of both   all  HT and   s  HT, although 1 individual study   [15]   suggested 
higher triglyceride levels in   s HT.
    Therefore, the association between lipid profile and risk of HT is likely to be mediated 
by LDL cholesterol. This result is important because LDL cholesterol may be influenced by 
statins. The question of whether rt-PA is safe in patients with low LDL cholesterol levels or 
on statin treatment is therefore important: although patients treated with statins have less 
severe cerebral infarcts  [25] , a large European multicenter study showed that this effect is lost 
in patients treated concomitantly with rt-PA   [26]  . The underlying mechanism of increased 
HT with low levels of LDL cholesterol is not established. Cholesterol may be important for 
the integrity of small vessels   [8]   and of the neurovascular unit.
    Although the mechanisms of HT and spontaneous ICH are different, it should be em-
phasized that the results of this meta-analysis mirror the findings of the INTERSTROKE 
  [27]   study showing a link between low LDL cholesterol and the risk of spontaneous ICH but 
not with those of SPARCL showing no relation between a low LDL cholesterol level and the 
risk of ICH   [10]  .
Table 3. D  escription of predictors of HT 
Bang
et al. [13]
Montaner
[14]
Uyttenboogaart
et al. [15]
Kim
et al. [16]
Meier
et al. [17]
Restrepo
et al. [18]
Bang
et al. [19]
Paciaroni
et al. [20]
2007 2008 2008 2009 2009 2009 2009 2009
(n = 104) (n = 60)a (n = 252)b (n = 377) (n = 311) (n = 142) (n = 26)c (n = 491)d
Ongoing anticoagulation at stroke onset reported + – – +++++
Ongoing antiplatelet therapy at stroke onset reported + + + +++++
Acute treatment with intravenous rt-PA reported + + + +++++
Acute treatment with intra-arterial thrombolytic
therapy reported
+–– –+++–
Acute treatment with intra-arterial mechanical
device reported
+–– –+++–
Anticoagulant therapy received before assessment
of HT reported
??? ?–??+
Treatment with antiplatelet therapy received
before assessment of HT
??? ?+ ??+
Prior arterial hypertension reported + + + +++++
Admission blood glucose level provided + – + + – + + +
Admission blood pressure provided + – + + – + + +
Admission NIHSS score provided + + + +++++
Presumed causes detailed + + – +++–+
Location of cerebral infarct detailed – + – +++++
Infarct volume reported on DWI – ? NA –––+N A
ASPECT score reported – ? – –––––
Presence of leukoaraiosis reported – – – + ––––
Presence of silent infarcts reported – – – –––––
Presence of microbleeds reported – – – + ––––
Previous symptomatic stroke lesion reported – – – + ––––
+   = Characteristics fulfilled; – = characteristics not fulfilled; ? = unknown; NA = not applicable; DWI = diffusion-weighted imaging; 
ASPECT = Alberta Stroke Program Early CT Score.
a Among 145 patients, 60 were evaluated for the association between HT and lipid profile. 
b Among 301 patients, 252 were evaluated for the association between HT and lipid profile. 
c Among 127 patients, 26 were evaluated for the association between HT and lipid profile. 
d Among 1,125 patients, 491 were evaluated for the association between HT and lipid profile. 137
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Table 4. M  ethod of the analysis
Bang
et al. [13]
Montaner
[14]
Uyttenboogaart
et al. [15]
Kim
et al. [16]
Meier
et al. [17]
Restrepo
et al. [18]
Bang
et al. [19]
Paciaroni
et al. [20]
2007 2008 2008 2009 2009 2009 2009 2009
(n = 104) (n = 60)a (n = 252)b (n = 377) (n = 311) (n = 142) (n = 26)c (n = 491)d
Missing data, %
HT 0 0 0 0 0 0 0 0
Total cholesterol ? 0 0 0 1 ? ? NA
LDL cholesterol 13 0 0 6.9 10.9 ? ? ?
HDL cholesterol ? 0 0 6.9 6.7 NA ? NA
Triglycerides ? 0 0 6.9 5.4 NA NA NA
Lipids levels presented as continuous variables + + + + + + + +
Comparison of 2 groups with and without
allHT – – – + + – – –
sHT + + + – + – – –
Multivariate analysis with
HT as dependent variable + – + + + – – –
Lipid levels as independent variables + – + + + – – –
+   = Characteristics fulfilled; – = characteristics not fulfilled; ? = unknown; NA = not applicable. 
a Among 145 patients, 60 were evaluated for the association between HT and lipid profile. 
b Among 301 patients, 252 were evaluated for the association between HT and lipid profile. 
c Among 127 patients, 26 were evaluated for the association between HT and lipid profile. 
d Among 1,125 patients, 491 were evaluated for the association between HT and lipid profile. 
Study Year WMD (95% CI) Weight, %
Total cholesterol level
Kim et al. [16] 2009 –6.60 (–16.45, 3.25) 61.33
Meier et al. [17] 2009 –5.00 (–17.41, 7.41) 38.67
(I2 = 0.0%, p = 0.843) –5.98 (–13.70, 1.73) 100.00
LDL cholesterol level
Kim et al. [16] 2009 –9.30 (–17.22, –1.38) 63.56
Meier et al. [17] 2009 –7.40 (–17.86, 3.06) 36.44
(I2 = 0.0%, p = 0.777) –8.61 (–14.92, –2.29) 100.00
HDL cholesterol level
Kim et al. [16] 2009 2.00 (–1.71, 5.71) 57.35
Meier et al. [17] 2009 3.50 (–0.81, 7.81) 42.65
(I2 = 0.0%, p = 0.605) 2.64 (–0.17, 5.45) 100.00
Triglycerides
Kim et al. [16] 2009 0.90 (–14.95, 16.75) 79.20
Meier et al. [17] 2009 0.90 (–30.02, 31.82) 20.80
(I2 = 0.0%, p = 1.000) 0.90 (–13.20, 15.00) 100.00
0
Favors no HT Favors HT
  Fig. 2.   Influence of lipid profiles on HT risk in ischemic stroke patients.  138
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Table 5. C  omparison of lipid profiles in patients with and without HT
HT p
values
Multivariable analysis
OR (95% CI)
present absent
n mean (SD) n mean (SD)
Any type of HT
Total cholesterol level
Kim et al. [16], 2009 74 176.08 (38.31) 303 182.66 (40.63) 0.210 0.85 (0.64–1.12) 
for 38.67 mg/dl increase
Meier et al. [17], 2009  64 197.60 (44.85) 247 202.63 (46.04) 0.418 NR
LDL cholesterol level
Kim et al. [16], 2009  74 104.87 (30.18) 303 114.16 (34.83) 0.045 0.72 (0.51–1.03) 
for 38.67 mg/dl increase
Meier et al. [17], 2009 64 112.14 (37.89) 247 119.49 (38.67) 0.220 NR
HDL cholesterol level
Kim et al. [16], 2009 74 45.27 (15.09) 303 43.34 (12.38) 0.660 NR
Meier et al. [17], 2009 64 56.45 (15.85) 247 52.97 (14.69) 0.111 NR
Triglycerides
Kim et al. [16], 2009 74 116.02 (61.99) 303 115.14 (63.77) 0.890 NR
Meier et al. [17], 2009 64 156.76 (113.36) 247 155.88 (108.94) 0.839 NR
Symptomatic HT
Total cholesterol level
Bang et al. [13], 2007 17 141.40 (40.9) 87 173.30 (39.2) 0.005 NR
Montaner [14], 2008 5 215.94 55 221.80 0.860 NR
Uyttenboogaart et al. [15], 2008 13 197.22 (46.40) 239 197.22 (46.40) 0.900 0.73 (0.40–1.34) 
for 38.67 mg/dl increase
Meier et al. [17], 2009  15 197.60 (46.40) 247 202.63 (46.04) 0.720 NR
LDL cholesterol level
Bang et al. [13], 2007 17 77.90 (40.5) 87 106.00 (32.5) 0.006 0.96 (0.941–0.995) 
for 38.67 mg/dl increase
Montaner [14], 2008 5 139.05 55 135.53 0.820 NR
Uyttenboogaart et al. [15], 2008 13 116.01 (30.94) 239 119.88 (38.67) 0.030 NR
Meier et al. [17], 2009 15 113.68 (35.18) 247 119.49 (38.67) 0.548 NR
HDL cholesterol level
Bang et al. [13], 2007 17 45.30 (13.6) 87 47.60 (12.3) 0.526 NR
Montaner [14], 2008 5 49.70 55 56.63 0.270 NR
Uyttenboogaart et al. [15], 2008 13 38.67 (11.60) 239 46.40 (19.34) 0.730 NR
Meier et al. [17], 2009 15 59.55 (18.17) 247 52.97 (14.69) 0.205 NR
Triglycerides
Bang et al. [13], 2007 17 97.90 (42.1) 87 103.50 (69.4) 0.772 NR
Montaner [14], 2008 5 135.94 55 148.14 0.660 NR
Uyttenboogaart et al. [15], 2008 13 221.43 (150.57) 239 159.43 (97.43) 0.020 2.16 (1.20–3.91) 
for 88.57 mg/dl increase
Meier et al. [17], 2009 15 164.74 (117.79) 247 155.88 (108.94) 0.951 NR
Lipid levels are provided in mg/dl. n = Number of patients; NR = not reported.139
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  P e r s p e c t i v e  
  This systematic review suggests that patients with low LDL cholesterol levels have an 
increased risk of HT, but is not conclusive for the influence of HDL, and suggests no influ-
ence of triglyceride levels. The results of the meta-analysis are limited by methodological is-
sues: (i) lipid profiles were not determined specifically to address the question of the relation-
ship with HT in 7 studies and were heterogeneously assessed; (ii) no study was conducted to 
test the hypothesis that is the subject of this meta-analysis, and (iii) heterogeneity for the 
method of assessment of HT and unclear definition of HT or of its symptomatic presenta-
tion. Therefore, there is a risk that unmeasured biases could have affected the results.
    The main limitations of this study are that: (i) none of them was designed to address the 
study question; (ii) the HT definitions were not consistent among studies, and (iii) there were 
significant issues related to the measurement of lipid parameters. Therefore, these limitations 
of the data make conclusion quite weak unless confirmed by another large and properly de-
signed study. The questions that should be addressed now are: (i) what is the mechanism of this 
increased risk of HT with low levels of LDL? (ii) Do statins contribute to the increased risk of 
HT or do anti-inflammatory properties of statins counterbalance this effect? (iii) Are these 
results valid in patients who were treated with rt-PA? Prospective studies recruiting non-select-
ed ischemic stroke patients (treated or not by rt-PA) and designed specifically for that purpose 
as well as studies in animal models are required to solve these issues.
Study Year WMD (95% CI) Weight, %
Total cholesterol level
Bang et al. [13] 2007 –31.90 (–53.02, –10.78) 36.39
Montaner [14] 2008 –5.90 (–43.22, 31.42) 11.65
Uyttenboogaart et al. [15] 2008 0.00 (–25.90, 25.90) 24.19
Meier et al. [17] 2009 –5.00 (–29.17, 19.17) 27.77
(I2 = 34.7%, p = 0.204) –13.68 (–26.42, –0.95) 100.00
LDL cholesterol level
Bang et al. [13] 2007 –28.10 (–48.53, –7.67) 25.64
Montaner [14] 2008 3.60 (–32.92, 40.12) 8.02
Uyttenboogaart et al. [15] 2008 –3.90 (–21.40, 13.60) 34.94
Meier et al. [17] 2009 –5.80 (–24.26, 12.66) 31.41
(I2 = 28.8%, p = 0.239) –10.10 (–20.44, 0.24) 100.00
HDL cholesterol level
Bang et al. [13] 2007 –2.30 (–9.26, 4.66) 34.17
Montaner [14] 2008 –6.90 (–19.26, 5.46) 10.85
Uyttenboogaart et al. [1] 2008 –7.70 (–14.46, –0.94) 36.20
Meier et al. [17] 2009 6.60 (–2.79, 15.99) 18.78
(I2 = 52.3%, p = 0.098) –3.08 (–7.15, 0.99) 100.00
Triglycerides
Bang et al. [13] 2007 –5.60 (–30.36, 19.16) 61.94
Montaner [14] 2008 –12.20 (–53.41, 29.01) 22.36
Uyttenboogaart et al. [15] 2008 62.00 (–20.79, 144.79) 5.54
Meier et al. [17] 2009 8.80 (–52.34, 69.94) 10.16
(I2 = 0.0%, p = 0.435) –1.87 (–21.36, 17.62) 100.00
0
Favors no sHT Favors sHT
  Fig. 3.   Influence of lipid profiles on the risk of   s  HT in ischemic stroke patients.  140
Cerebrovasc Dis Extra 2011;1:130–141 
 DOI:  10.1159/000335014 
EXTRA
  Nardi et al.: Lipids and Hemorrhagic Transformation of Stroke 
www.karger.com/cee
    © 2011 S. Karger AG, Basel
  Published online: December 29, 2011 
 References 
    1  The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plas-
minogen activator for acute ischemic stroke. N Engl J Med 1995;    333:   1581–1587. 
   2  Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, 
Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, 
Albers G, Bluhmki E, Wilhelm M, Hamilton S: Association of outcome with early stroke treatment: 
pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;    363:   768–774. 
    3  Larrue V, von Kummer R, del Zoppo G, Bluhmki E: Hemorrhagic transformation in acute ischemic 
stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997;   
 28:   957–960. 
    4  Molina CA, Alvarez-Sabin J, Montaner J, Abilleira S, Arenillas JF, Coscojuela P, Romero F, Codina 
A: Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, 
and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 2002;    33:  
 1551–1556. 
    5  Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, 
Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W, Allen K, Mau J, Meier D, del Zoppo G, 
De Silva DA, Butcher KS, Parsons MW, Barber PA, Levi C, Bladin C, Byrnes G: Time to treat-
ment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, 
ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;    375:   1695–1703. 
    6  Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, Davalos A: Plasma metallopro-
teinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003;   
 34:   40–46. 
    7  Bruno A, Levine SR, Frankel MR, Brott TG, Lin Y, Tilley BC, Lyden PD, Broderick JP, Kwiatkowski 
TG, Fineberg SE: Admission glucose level and clinical outcomes in the NINDS rt-PA stroke trial. 
Neurology 2002;    59:   669–674. 
    8  Reed DM: The paradox of high risk of stroke in populations with low risk of coronary heart disease. 
Am J Epidemiol 1990;    131:   579–588. 
    9  Chui D, Marotta J, Zang J, Liu Y, Rao M, Liu D: Influence of high cholesterol feeding on the pattern 
and progression of experimental cerebral ischemia. Biomed Pharmacother 1991;    45:   409–415. 
 10  Goldstein LB, Amarenco P, Callahan A 3rd, Hennerici M, Sillesen H, Welch KM: Hemorrhagic stroke 
in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008;    70:  
 2364–2370. 
  11  Higgins J, Green S: Cochrane Handbook for Systematic Reviews of Interventions. http://www.co-
chrane-handbook.org, 2009. 
  12  Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, 
Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-
Analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;    283:   2008–2012. 
  13  Bang OY, Saver JL, Liebeskind DS, Starkman S, Villablanca P, Salamon N, Buck B, Ali L, Restrepo L, 
Vinuela F, Duckwiler G, Jahan R, Razinia T, Ovbiagele B: Cholesterol level and symptomatic hemor-
rhagic transformation after ischemic stroke thrombolysis. Neurology 2007;    68:   737–742. 
  14  Montaner J: Cholesterol measured before stroke thrombolysis is not associated with tissue plasmin-
ogen activator-related hemorrhagic transformation. Stroke 2008;    39:e6. 
  15  Uyttenboogaart M, Koch MW, Koopman K, Vroomen PC, Luijckx GJ, De Keyser J: Lipid profile, 
statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. J Neurol 2008;   
 255:   875–880. 
  16  Kim BJ, Lee SH, Ryu WS, Kang BS, Kim CK, Yoon BW: Low level of low-density lipoprotein choles-
terol increases hemorrhagic transformation in large artery atherothrombosis but not in cardioem-
bolism. Stroke 2009;    40:   1627–1632. 
   Disclosure  Statement 
   N o n e  .    141
Cerebrovasc Dis Extra 2011;1:130–141 
 DOI:  10.1159/000335014 
EXTRA
  Nardi et al.: Lipids and Hemorrhagic Transformation of Stroke 
www.karger.com/cee
  © 2011 S. Karger AG, Basel 
  Published online: December 29, 2011 
  17  Meier N, Nedeltchev K, Brekenfeld C, Galimanis A, Fischer U, Findling O, Remonda L, Schroth G, 
Mattle HP, Arnold M: Prior statin use, intracranial hemorrhage, and outcome after intra-arterial 
thrombolysis for acute ischemic stroke. Stroke 2009;    40:   1729–1737. 
  18  Restrepo L, Bang OY, Ovbiagele B, Ali L, Kim D, Liebeskind DS, Starkman S, Vinuela F, Duckwiler 
GR, Jahan R, Saver JL: Impact of hyperlipidemia and statins on ischemic stroke outcomes after intra-
arterial fibrinolysis and percutaneous mechanical embolectomy. Cerebrovasc Dis 2009;    28:   384–390. 
  19  Bang OY, Saver JL, Alger JR, Shah SH, Buck BH, Starkman S, Ovbiagele B, Liebeskind DS: Patterns 
and predictors of blood-brain barrier permeability derangements in acute ischemic stroke. Stroke 
2009;    40:   454–461. 
  20  Paciaroni M, Agnelli G, Corea F, Ageno W, Caso V, Silvestrelli G: Low levels of low-density lipopro-
tein cholesterol increase hemorrhagic transformation but not parenchymal hematoma in large artery 
atherothrombosis. Stroke 2009;     40:e544, author reply e545. 
  21  Jacobs DR Jr, Muldoon MF, Rastam L: Invited commentary: low blood cholesterol, nonillness mor-
tality, and other nonatherosclerotic disease mortality: a search for causes and confounders. Am J 
Epidemiol 1995;    141:   518–522. 
  22  Mendez I, Hachinski V, Wolfe B: Serum lipids after stroke. Neurology 1987;    37:   507–511. 
  23  Deplanque D, Gele P, Petrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, 
Cecchelli R, Staels B, Duriez P, Bordet R: Peroxisome proliferator-activated receptor-alpha activation 
as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 
2003;    23:   6264–6271. 
 24  Deplanque D, Leys D, Parnetti L, Schmidt R, Ferro J, de Reuck J, Mas JL, Gallai V: Secondary preven-
tion of stroke in patients with atrial fibrillation: factors influencing the prescription of oral anti-
coagulation at discharge. Cerebrovasc Dis 2006;    21:   372–379. 
  25  Deplanque D, Masse I, Lefebvre C, Libersa C, Leys D, Bordet R: Prior TIA, lipid-lowering drug use, 
and physical activity decrease ischemic stroke severity. Neurology 2006;    67:   1403–1410. 
  26  Engelter S, Soinne L, Ringleb P, Sarikaya H, Bordet R, Berrouschot J, Odier C, Arnold M, Ford G, 
Pezzini A, Zini A, Rantanen K, Rocco A, Bonati L, Kellert L, Strbian D, Stoll A, Meier N, Michel P, 
Baumgartner R, Leys D, Tatlisumak T, Lyrer P: IV thrombolysis and statins. Neurology 2011;    77:  
 888–895. 
  27  O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, 
McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusoff K, Truelsen 
T, Diener HC, Sacco RL, Ryglewicz D, Czlonkowska A, Weimar C, Wang X, Yusuf S: Risk factors for 
ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-
control study. Lancet 2010;    376:   112–123. 
  28  Berger C, Fiorelli M, Steiner T, Schabitz WR, Bozzao L, Bluhmki E, Hacke W, von Kummer R: Hem-
orrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke 2001;    32:  
 1330–1335. 
  